Early rheumatoid arthritis: Toward tailor-made therapy
- 27 Downloads
Therapeutic possibilities for the treatment of early rheuma-toid arthritis (RA) have expanded largely. New treatment modalities appear very effective with respect to relevant outcomes, such as radiographic progression. At the same time, the costs of disease-modifying antirheumatic drugs (DMARDs) have exponentially increased so that—given the rather high prevalence of RA—cost may become a limiting factor in the treatment of patients with RA. Therefore, there is a need to define the profile of those patients that should be treated with the most effective, and, unfortu-nately, the most costly, DMARDs. The authors describe herewith the heterogeneity of RA with respect to its most important outcomes, as well as the inability to predict those outcomes appropriately at the individual patient level. This heterogeneity of RA is not acknowledged in the mod-ern landmark clinical trials that the authors base therapeu-tic decisions on, and the external validity of those trials is at stake. In this article, the authors discuss the consequences of the heterogeneity of RA in light of the perceived lack of external validity of evidence-generating landmark trials. The authors propose the following solutions to overcome this discrepancy: 1) earlier recognition of RA, and 2) appropri-ate prediction of treatment efficacy, because the most chal-lenging scientific efforts may be taken in the near future in order to arrive at a tailor-made therapy for every individual presenting with RA.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 1.van der Horst-Bruinsma I.E.: Diagnosis and course of early-onset arthritis: results of a special early arthritis clinic compared to routine patient care. Br J Rheumatol 1998, 37:1084–1088. References [1 ], [2 ], and [3 ] are examples from early arthritis clinics (the Leiden early arthritis clinic [1 ], the Vienna early arthritis clinic [2 ], and the Norfolk Arthritis Register [3 ]), with a slightly different spectrum of patients included.PubMedCrossRefGoogle Scholar
- 2.Machold KP: Very recent onset arthritis: clinical, laboratory, and radiological findings during the first year of disease. J Rheumatol 2002, 29:2278. References [1 ], [2 ], and [3 ] are examples from early arthritis clinics (the Leiden early arthritis clinic [1 ], the Vienna early arthritis clinic [2 ], and the Norfolk Arthritis Register [3 ]), with a slightly different spectrum of patients included.PubMedGoogle Scholar
- 3.Harrison B: Early inflammatory polyarthritis: results from the Norfolk Arthritis Register with a review of the literature, II: outcome at three years. A simple algorithm to predict the development of radiological erosions in patients with early rheumatoid arthritis: prospective cohort study. Measuring outcome in rheumatoid arthritis: which measures are suit-able for routine clinical use? Rheumatology 2000, 39:939–949. References [1 ], [2 ], and [3 ] are examples from early arthritis clinics (the Leiden early arthritis clinic [1 ], the Vienna early arthritis clinic [2 ], and the Norfolk Arthritis Register [3 ]), with a slightly different spectrum of patients included.PubMedCrossRefGoogle Scholar
- 4.Visser H: How to diagnose rheumatoid arthritis early: a pre-diction model for persistent (erosive) arthritis. Arthritis Rheum 2002, 46:357–365. Prediction algorithm for persistence and erosiveness for patients pre-senting with early arthritis. Unlike many other prognostic studies, this one is from the perspective of the individual patient.PubMedCrossRefGoogle Scholar
- 17.Bukhari M: Time to first occurrence of erosions in inflamma-tory polyarthritis: results from a prospective community-based study. Arthritis Rheum 2001, 44:1248–1253. Observational study on patients with early inflammatory arthritis. Highlights the discrepancies between radiographic progression at a group level and progression at an individual level. Contradicts the view of linear progression in the individual patient.PubMedCrossRefGoogle Scholar
- 23.Sokka T, Pincus T: Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis. Arthritis Rheum 2003, 48:313–318. Important observation regarding the external validity of landmark clinical trials. Only a minority of patients in common clinical practice would have met the in- and exclusion criteria of trials with tumor necrosis factor-blocking drugs.PubMedCrossRefGoogle Scholar
- 24.Bukhari MA: Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. Arthritis Rheum 2003, 48:46–53. Observational study on patients with early arthritis, of whom the majority did not fulfil the American College of Rheumatology criteria for RA at baseline. The authors use unprecedented methodology to prove that an early DMARD start retards radiographic progression bet-ter than a delayed DMARD start.PubMedCrossRefGoogle Scholar
- 25.Lard LR: Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001, 111:446–451. One of the very few clinical trials demonstrating the efficacy of early DMARD treatment.PubMedCrossRefGoogle Scholar